Cerebrolysin (Cerebrolysin®)
Neuropeptide Preparation | Neurological Recovery
Community Research
Join others researching Cerebrolysin — share findings, ask questions, and learn from real experiences
Standardized neuropeptide preparation containing bioactive peptides and amino acids exhibiting neurotrophic and neuroprotective properties for stroke recovery, traumatic brain injury, and cognitive enhancement. Used clinically in 50+ countries.
IV/IM administration provides optimal bioavailability and brain penetration of neuropeptides and neurotrophic factors.
Molecular Data
Bioactive peptide mixture Complex or non-standard sequence format
Research Indications
Meta-analyses show modest cognitive improvements, though clinical significance remains debated.
Multiple RCTs demonstrate significant ADAS-cog and CIBIC+ improvements.
Large meta-analysis shows significant NIHSS improvements; other studies found no functional benefit.
Largest meta-analysis (1,879 patients) shows NIHSS benefits; independent analysis found no mRS improvement.
Multiple trials including CAPTAIN series confirm GCS/GOS improvements.
Pilot trial shows promising 6-month outcomes; requires larger confirmatory studies.
Some studies show enhanced recovery; results vary significantly between trials.
Early administration within 72 hours shows better outcomes than delayed treatment.
Dosing Protocols
Primary administration route with well-established protocols for direct brain delivery via IV/IM.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Small Volume IV | Up to 10mL | Once daily | Undiluted IV slow push over 3 minutes |
| Intramuscular | Up to 5mL | Once daily | Undiluted IM injection over 3 minutes |
| Acute Stroke | 20-50mL | Once daily for 10-21 days | IV infusion (diluted to 100mL minimum) |
| Traumatic Brain Injury | 20-50mL | Once daily for 7-30 days | IV infusion (diluted to 100mL minimum) |
| Alzheimer's Disease | 10-30mL | 5 days weekly for 4 weeks | IV injection/infusion (2-4 cycles yearly) |
| Vascular Dementia | 10-30mL | 5 days weekly for 4 weeks | IV injection/infusion (2-4 cycles yearly) |
Reconstitution Instructions
- Cerebrolysin ampoules (5, 10, or 20 mL)
- Saline, Ringer solution, or 5% glucose (minimum 100 mL for infusion)
- Disposable one-way IV infusion sets and cannulas
- Sterile syringes and alcohol swabs
- 1 Break ampoule and extract Cerebrolysin immediately before use
- 2 For direct injection: Up to 10 mL IV undiluted (slow 3 minutes) or 5 mL IM
- 3 For infusion: Dilute 10-50 mL to minimum 100 mL with compatible solution
- 4 Start infusion immediately after dilution—infuse within 15 minutes
- 5 Flush IV catheter with sodium chloride before and after administration
- 6 Use disposable one-way infusion sets; discard after use
Interactions
What to Expect
Side Effects & Safety
Common Side Effects
- Generally well tolerated
- Possible mild dizziness or agitation in early treatment
Stop Signs - Discontinue if:
- Severe allergic reactions (anaphylaxis, severe rash)
- New onset seizure activity
- Significant cardiovascular events during administration
- Severe renal dysfunction or worsening kidney function
Contraindications
- Epilepsy
- Severe renal insufficiency
- History of severe allergic reactions to porcine products
Quality Checklist
Good Signs
- Clear amber solution from reputable source
- Room temperature storage ≤25°C
- Protected from light in original carton
- Authorized EVER Pharma distributor
Warning Signs
- Some published studies have been retracted due to research misconduct; rely on independent meta-analyses
Bad Signs
- Frozen product or improper storage—never freeze
- Mixing with incompatible solutions (amino acids, vitamins, cardiovascular medications)
References
- Efficacy and Safety of Cerebrolysin in Neurorecovery After Moderate-Severe Traumatic Brain Injury: Results from the CAPTAIN II TrialMuresanu DF, Florian S, et al.Neurological Sciences (2020)
Phase IIIb/IV RCT: patients with GCS 7-12 received 50 mL Cerebrolysin daily for 10 days + two additional 10 mL cycles; confirmed beneficial effects on overall outcome after moderate-severe TBI.
- Safety and Efficacy of Cerebrolysin in Early Post-Stroke Recovery: A Meta-Analysis of Nine Randomized Clinical TrialsBornstein NM, Guekht A, Vester J, et al.Neurological Sciences (2018)
Meta-analysis of 1,879 stroke patients showed NIHSS superiority of Cerebrolysin (MW 0.60, P < 0.0001); NNT = 7.7 for clinically relevant early neurological improvement.
- Cerebrolysin for Functional Recovery in Patients with Acute Ischemic Stroke: A Meta-Analysis of Randomized Controlled TrialsXue LX, Zhang T, Zhao YW, et al.International Journal of Neuroscience (2017)
Meta-analysis of 1,779 patients found no significant benefit on mRS response (RR 1.33, P=0.28) or Barthel Index; concluded routine use for long-term stroke rehabilitation not supported.
- Cerebrolysin in Patients with TBI: Systematic Review and Meta-AnalysisJarosz K, Kojder K, Andrzejewska A, Solek-Pastuszka J, Jurczak ABrain Sciences (2023)
10 studies of 8,749 TBI patients; GOS improvement was statistically significant (mean difference 0.422, P = 0.000); mortality and length of stay were not significantly affected.
- Cerebrolysin in Mild-to-Moderate Alzheimer's Disease: A Meta-Analysis of Randomized Controlled Clinical TrialsGauthier S, Proano JV, Jia J, et al.Dementia and Geriatric Cognitive Disorders (2015)
6 RCTs in mild-to-moderate AD; Cerebrolysin significantly superior to placebo on ADAS-cog at 4 weeks (SMD -0.40, P=0.003) and CIBIC global clinical change at 4 weeks and 6 months.
Disclaimer
This information is for educational and research purposes only. Consult a healthcare professional before use.